Fate Therapeutics Inc (FATE)

[jondoeuk]

AACR abstracts

Detection of genetically engineered iPSC-derived natural killer cells in blood and tissue https://www.abstractsonline.com/pp8/#!/10517/presentation/13839

Combining dual CAR iPSC-derived immune cells with antibody for multi-antigen targeting to overcome clonal resistance in multiple myeloma https://www.abstractsonline.com/pp8/#!/10517/presentation/16806

A novel synthetic stealth receptor that redirects host immune cell alloreactivity and potentiates functional persistence of adoptively transferred off-the-shelf cell-based cancer therapy https://www.abstractsonline.com/pp8/#!/10517/presentation/16749

FT573: Preclinical development of multiplexed-engineered iPSC-derived NK cells expressing a novel camelid nanobody chimeric antigen receptor (CAR) targeting pan-cancer antigen B7-H3 https://www.abstractsonline.com/pp8/#!/10517/presentation/16570

Multiplexed-engineered, iPSC-derived T cells expressing three unique targeting modalities address tumor heterogeneity and antigen escape https://www.abstractsonline.com/pp8/#!/10517/presentation/16565

Chimeric CD3 fusion receptors expressed on iPSC-derived universal TCR-less CAR-T and -NK cells synergize with bispecific engagers to enhance antitumor activity and limit antigen escape https://www.abstractsonline.com/pp8/#!/10517/presentation/17732